Weighing up the pros and cons of adopting a piecemeal versus a full automation approach to cell therapy manufacture

Cell & Gene Therapy Insights 2024; 10(4), 571–578

DOI: 10.18609/cgti.2024.069

Published: 21 May
Raymond Luke

While the menu of automated cell therapy processing solutions continues to grow apace, the difficulty in deciding precisely when and what to automate remains frustratingly consistent. David McCall, Senior Editor, BioInsights, speaks to Raymond Luke, Head of CMC, Director of Manufacturing Science and Technology at Verismo Therapeutics, about the critical considerations for early-stage biotechs in shaping an automation strategy that will stand the test of time.